Majority Leader Steny Hoyer (D-Md.) said House Democrats plan to vote Thursday — or at the latest Friday — on the nearly $2 trillion Build Back Better Act, which contains…

AbbVie’s rheumatoid arthritis drug Humira (adalimumab) and six other drugs whose prices were raised in 2020 without supportive clinical data cost the U.S. health system $1.67 billion in annual drug…

Pfizer has filed its application with the FDA for Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid, for the treatment of mild-to-moderate COVID-19 in patients at increased…

The pandemic forced the FDA to be far more innovative in its efforts to inspect drug and device manufacturing facilities, and the agency plans to incorporate these new modalities into…

A trial pitting Washington state against the three largest U.S. drug distributors began yesterday, with the state seeking more than $38 billion in damages from the companies for their alleged…

Aduhlem is contributing to a 14.5 percent increase in 2022 Medicare Part B premiums, even though the Centers for Medicare and Medicaid Services (CMS) hasn’t yet decided whether it will…

The Federal Trade Commission (FTC) has approved certain modifications to Bristol Meyers Squibb’s (BMS) divestiture agreements as part of the company’s 2019 acquisition of Celgene. Source: Drug Industry Daily

A federal judge in Pennsylvania is allowing a trial to proceed against Merck alleging the company’s Zostavax shingles vaccine induced the disease instead of preventing it. Source: Drug Industry Daily

When the FDA gets tough on clinical trial transparency, the industry listens. The problem is the FDA doesn’t get tough with enough regularity. Source: Drug Industry Daily

The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) not offer BioMarin Pharmaceutical’s Vimizim (elosulfase alfa) for treating mucopolysaccharidosis type 4A…